Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes
Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
A Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine Alone in Patients with Metastatic Melanoma
A Phase II Study of Single Agent Gemcitabine in Relapsed or Refractory Follicular or Small Lymphocytic non-Hodgkin’s Lymphomas
A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Daily Oral Etoposide Plus Ifosfamide Plus Cisplatin for Previously Treated Recurrent Small-Cell Lung Cancer
A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Unresectable Non-small Cell Lung Cancer (NSCLC)
A Phase II Trial of CODE (Cisplatin, Vincristine, Doxorubicin, Etoposide) Plus Granulocyte-Colony Stimulating Factor (G-CSF) in Advanced Non-Small Cell Lung Cancer
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
Maintenance Daily Oral Etoposide versus No Further Therapy Following Induction Chemotherapy with Etoposide plus Ifosfamide plus Cisplatin in Extensive Small-Cell Lung Cancer: A Randomized Trial
Etoposide, Ifosfamide and Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer (SCLC): A Phase II study
A Phase II Study of Gemcitabine Plus Paclitaxel in Patients With Previously Untreated Stage IIIb and IV Non-Small Cell Lung Cancer
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC: A Hoosier Oncology Group (HOG) phase II study
Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-small Cell Lung Cancer Previously Treated with Chemotherapy
Randomized Phase II Trial Comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
Gefitinib in Patients with Chemo-sensitive and Chemo-refractory Relapsed Small Cell Cancers: A Phase II Trial
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC)
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
Gefitinib plus Celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study
Cisplatin plus Etoposide plus Concurrent Chest Radiation with or without Consolidation Docetaxel in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Study
Pemetrexed plus Cetuximab in patients with Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I/II Study
Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study
Dose Volume Analysis of Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Concurrent Cisplatinum and Etoposide with or without Consolidation Docetaxel
Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer, a Phase II Study
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial
Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies
Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer
